Swedish Orphan Biovitrum (Sobi) and Bioverativ will present new haemophilia data at the 10th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place in Paris, France, 1-3 February 2017.
Nine abstracts from Sobi- and Bioverativ-led studies have been accepted for presentation during EAHAD, reflecting the companies’ commitment to the haemophilia community. The nine posters include data on the long-term safety and efficacy of the companies’ extended half-life therapies, Elocta (efmoroctocog alfa), marketed as ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the United States, Japan and Canada, and Alprolix (eftrenonacog alfa), in people of all ages with haemophilia A and B, respectively, providing an updated analysis of long-term data from the registration studies ASPIRE and B-YOND.
“Sobi and Bioverativ are committed to supporting the haemophilia community to better understand the potential of extended half-life factor treatments,” says Krassimir Mitchev, MD, PhD, vice president and medical therapeutic area head of Haemophilia at Sobi. “These data present how to individualise dosing and consumption in order to gain a comprehensive protection beyond prevention of bleeds.”
“These data provide additional insights for physicians and people living with haemophilia, and reinforce the well-characterised safety and efficacy profile for Elocta/ELOCTATE and Alprolix. These are the only haemophilia therapies utilizing Fc fusion technology, which uses the body’s natural pathway to prolong the time the therapy remains in the body,” said Maha Radhakrishnan, MD, senior vice president of medical at Bioverativ.